Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Oct 23, 2025
- Closes
- Nov 23, 2026 (in 44 days)
Similar opportunities open now
- Cellular Senescence Network (SenNet): SenNet Data Coordination and Integration Center (SenNet DCIC) (UM1 Clinical Trials Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 23, 2026 (in 44 days)
- Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 23, 2026 (in 44 days)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026 (in 31 days)Up to $300K
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026 (in 31 days)Up to $150K
- NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 2029
Classification and identifiers
- Solicitation number
- RFA-RM-27-007
- Assistance listing (CFDA)
- 93.310
Amount
Amount not listed here. Check the official program.
Who can apply
Private colleges and universities can apply here. Check the eligibility details below to see if your organization fits.
About this opportunity
The NIH Common Fund, National Institute on Aging, National Cancer Institute and additional NIH Institutes and Centers (ICs) intend to publish a Notice of Funding Opportunity (NOFO) to solicit applications for Stage 2 of the Cellular Senescence Network (SenNet) Program, which seeks to understand the biological consequences of senescent cell heterogeneity in health and disease, identify and characterize tissue-specific senescence markers in human biospecimens to facilitate the development of senotherapeutic strategies that improve health outcomes. The program’s Senescence Technology Projects (SenTecs) will develop innovative tools and technologies that consider the complex nature of senescence to facilitate identification, characterization and targeting of senotypes in vivo. Applications are...